SIGN UP

top stories

Danish biotech Gubra touts early weight loss data in hot amylin field

4 hours ago

Drug inspector attrition leads to 'many fewer' checks than 2016 peak, GAO says

5 hours ago

J&J takes 340B fight with federal government to court

7 hours ago

89bio’s $125M offering; Another FDA hold for Kezar

8 hours ago

Latest

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

8 hours ago

Primary care unicorn startup Forward Health shuts down

8 hours ago

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

9 hours ago

Otsuka and ICU Medical forge IV manufacturing network to supply the US

10 hours ago

After stock slides, Amgen addresses bone density talk on obesity drug

11 hours ago

TRexBio raises $84M to take in-house immune program into the clinic

12 hours ago

see latest stream

People

Exclusive: Flagship names two CEO-partners to lead Valo Health, Apriori Bio

12 hours ago

Thermo Fisher consolidates viral vector work in Massachusetts, cuts 160 workers

2 days ago

Senior AstraZeneca exec detained in China amid wider investigation

6 days ago

Financing

Exclusive: GV-backed Medicaid startup Diverge Health raises $52M

Yesterday

Alentis nabs $181M to broaden Claudin's scope in ADCs

Yesterday

Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work

Yesterday

Startups

Roche teams with Flare Therapeutics on transcription factors

Yesterday

GSK snags Parkinson's drug from Flagship startup Vesalius

Yesterday

Yorvipath’s approval showcases biopharma’s interest in rare endocrine disorder

2 days ago

Deals

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

12 hours ago

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

Yesterday

Cigna says it will not pursue a merger with Humana

2 days ago

In FocusSee all

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Last week

Is there room for MASH drugs in a GLP-1 world?

Last week

Bad trip: How culture conflict and a need for cash nearly broke Lykos

Last month

Recursion nears ‘moment of truth’ with first key data, kicking off 18-month flurry of readouts

2 months ago

Endpoints Standouts

How the world's biggest pharma and biotech companies paid their typical worker in 2023

4 months ago

In biotech's uneven recovery, 50 startups raised megarounds in first half of 2024

4 months ago

Biopharma leaders charting a path for the industry's LGBTQ+ community

4 months ago

Peter Marks single-handedly approved Sarepta’s gene therapy — what does that mean for everyone else?

4 months ago

Peer review See all

Nov

8

Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down

Nov

1

Biogen brings in medical chief as CFO plans retirement; MacroGenics CEO announces departure

Oct

25

Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson

Oct

18

Exclusive: Ex-Affimed CEO heads to UK nanomedicine biotech; Jami Rubin leaves Boundless Bio after IPO

Oct

11

Lilly follows the trend of new AI hires; Pfizer fills key UK position as activist hubbub swells

Pharma channel feed

Yesterday

Pfizer looking to sell hospital drugs unit — reports

Pfizer is reportedly shopping its hospital drugs unit as it fends off scrutiny from activist investor Starboard Value.

READ MORE

AstraZeneca CEO reaffirms commitment to China following executive's detention

Yesterday

Syndax's menin inhibitor succeeds in pivotal trial, but investors aren't impressed

Yesterday

latest in Pharma

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Yesterday

Intercept is denied full FDA approval for Ocaliva, but claims it will keep drug on market

Yesterday

Updated: AstraZeneca, Daiichi Sankyo replace lung cancer filing for Enhertu successor

Yesterday

Bayer not eyeing new deals to address Xarelto sales erosion

Yesterday

23andMe to shut down its therapeutics division

2 days ago

see latest stories

Marketing channel feed

Last month

Valneva and Pfizer eye 2027 launch for partnered Lyme disease vaccine

Valneva is eyeing a 2027 launch for its Pfizer-partnered Lyme disease vaccine, CEO Thomas Lingelbach said Thursday during the company’s investor day.

READ MORE

UK watchdog criticizes Moderna for Covid-19 trial's use of WhatsApp to dangle payments to children

Last month

FDA criticizes AbbVie's 'misleading' ad with Serena Williams

2 months ago

latest in Marketing

Updated: Madrigal finally reveals first wave of sales for MASH drug Rezdiffra

3 months ago

RSV market pressure leads to slower launch for Moderna's vaccine

3 months ago

Verona inks financing deal worth up to $650M ahead of COPD decision

6 months ago

From the editor: Our final edition of Endpoints MarketingRx

6 months ago

MarketingRx roundup: Moderna debuts social media science series; Boehringer expands NY mental health exhibit

6 months ago

see latest stories

FDA+ channel feed

Yesterday

'Expertise is a real thing': FDA commissioner warns of political risk to agency

With just a few months to go before he likely steps down, President Biden's FDA Commissioner Rob Califf weighed in on how the agency might be affected by the incoming administration.

READ MORE

Rapt cuts immunology program following clinical holds

2 days ago

FDA records request lands Chinese API manufacturer on blocked import list

5 days ago

latest in FDA+

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

6 days ago

FDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacy

6 days ago

California voters say yes to restrictions around 340B spending

Last week

New Trump era could be a boon for biopharma M&A, dealmaking

Last week

Acadia lands $150M sale of rare pediatric PRV

Last week

see latest stories

Manufacturing channel feed

Yesterday

AstraZeneca budgets another $2B to boost manufacturing and R&D in US

Among a flurry of third-quarter updates on Tuesday, AstraZeneca said it is earmarking an additional $2 billion to add 1,000 new jobs in the US.

READ MORE

Coherus restarts biosimilar supply after delays; Novavax ends Covid vaccine deal with UK

6 days ago

Avid Bioservices to be sold to private equity firms for $1.1B

6 days ago

latest in Manufacturing

Catalent touts customer confidence ahead of Novo deal, but misses revenue estimates

Last week

Nektar divests manufacturing site and reagent arm for $90M

Last week

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Last week

European Commission marks Dec. 6 for Novo-Catalent deal decision

Last week

Baxter pulls IV products out of China to shift supply to the US

Last week

see latest stories